Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

The National Joint Procurement Office issued the Announcement on the Information Change Work for Selected Products in National Organization of Drug Volume‑Based Procurement, permitting – when selected enterprises and their…

Genentech's Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

Genentech’s Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

HutchMed's Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

HutchMed’s Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Shanghai Pharmaceuticals' B019 Injection Approved for SLE Clinical Trials
CompanyDrug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01
CompanyDrug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30
CompanyDrug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials
CompanyDrug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Hengrui Pharmaceuticals' HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval
CompanyDrug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer
CompanyDrug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Kelun-Biotech's SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment
CompanyDrug

Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment

Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases
CompanyDrug

Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases

Show More